Kyntra Bio, Inc. (KYNB) vs NextCure, Inc. (NXTC)
A side-by-side comparison of Kyntra Bio, Inc. and NextCure, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KYNB
Kyntra Bio, Inc.
$5.92HealthcareDelayed quote: Oct 6, 2026, 2:42 PM EDT
NXTC
NextCure, Inc.
$5.34HealthcareDelayed quote: Oct 6, 2026, 2:44 PM EDT
Total return — KYNB vs NXTC
growth of $100 · dividends reinvested · last 7yKYNB -99.5% (-52.8%/yr)NXTC -97.9% (-42.4%/yr)NXTC compounded faster over this window
KYNB NXTC
KYNB vs NXTC: by the numbers
- •KYNB is the larger company ($24M vs $19M market cap).
- •KYNB is profitable (3967.77% net margin) while NXTC runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | KYNB | NXTC |
|---|---|---|
| P/S ratio | 5.19 | N/A |
| P/B ratio | N/A | 1.59 |
Profitability
| Metric | KYNB | NXTC |
|---|---|---|
| Gross margin | 91.37% | 0.00% |
| Operating margin | -712.66% | 0.00% |
| Net margin | 3967.77% | 0.00% |
| ROE | N/A | -351.86% |
| ROIC | -78.16% | -259.91% |
Growth (annualized)
| Metric | KYNB | NXTC |
|---|---|---|
| Revenue CAGR (5Y) | -51.49% | N/A |
| Total return CAGR (5Y) | -52.67% | -44.29% |
Frequently asked
- Is KYNB or NXTC more profitable?
- KYNB runs the higher net margin — KYNB at 3967.77% versus NXTC at 0.00%.
- How have KYNB and NXTC total returns compared?
- Over the past 5 years, KYNB delivered -52.67% and NXTC delivered -44.29% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.